- Field Trip Health (OTCQX:FTRPF) has received final approval from The NASDAQ for listing its common shares under the symbol, "FTRP".
- The shares will start trading on the NASDAQ Global Select Market at market open on July 29, 2021.
- Concurrent with the listing, Ellen Lubman and Ronan Levy will join the compensation committee and Ryan Yermus and Mujeeb Jafferi will resign as directors of the company. Yermus and Jafferi will continue as Chief Clinical Officer and Chief Operating Officer, respectively.
- Yermus commented, "We continue to make steady progress with the development of FT-104, a novel psychedelic molecule, with GMP production underway in preparation for Phase 1 studies, and other strategic initiatives which will further strengthen our leadership position in the industry. Listing on the leading securities exchange for biotech companies will enable more investors both in the U.S. and globally to support Field Trip as we advance our ground-breaking work in the psychedelics industry."
- Previously (July 23): Field Trip Health received conditional approval to list on Nasdaq